CGAS and nervous system disorder: cGAS−/− mice receiving diABZI-4 were protected from HSV-1–induced weight loss (Fig. 1J), lethality (Fig. 1K), hydrocephalus (Fig. 1L) and symptoms of neurological disease (Fig. 1M).